- Home
- TLSI vs SDST Comparison
TLSI vs SDST Comparison
Compare TLSI & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- SDST
- Stock Information
- Founded
- TLSI 2010
- SDST 2022
- Country
- TLSI United States
- SDST United States
- Employees
- TLSI N/A
- SDST N/A
- Industry
- TLSI Medical Specialities
- SDST Blank Checks
- Sector
- TLSI Health Care
- SDST Finance
- Exchange
- TLSI Nasdaq
- SDST Nasdaq
- Market Cap
- TLSI 160.4M
- SDST 33.1M
- IPO Year
- TLSI N/A
- SDST N/A
- Fundamental
- Price
- TLSI $5.19
- SDST $0.54
- Analyst Decision
- TLSI Strong Buy
- SDST Strong Buy
- Analyst Count
- TLSI 6
- SDST 2
- Target Price
- TLSI $11.75
- SDST $1.73
- AVG Volume (30 Days)
- TLSI 34.3K
- SDST 496.9K
- Earning Date
- TLSI 05-14-2025
- SDST 05-14-2025
- Dividend Yield
- TLSI N/A
- SDST N/A
- EPS Growth
- TLSI N/A
- SDST N/A
- EPS
- TLSI N/A
- SDST N/A
- Revenue
- TLSI $29,431,000.00
- SDST N/A
- Revenue This Year
- TLSI $56.00
- SDST $4,114.37
- Revenue Next Year
- TLSI $52.17
- SDST N/A
- P/E Ratio
- TLSI N/A
- SDST N/A
- Revenue Growth
- TLSI 58.99
- SDST N/A
- 52 Week Low
- TLSI $3.50
- SDST $0.41
- 52 Week High
- TLSI $10.24
- SDST $28.38
- Technical
- Relative Strength Index (RSI)
- TLSI 40.35
- SDST N/A
- Support Level
- TLSI $4.66
- SDST N/A
- Resistance Level
- TLSI $5.35
- SDST N/A
- Average True Range (ATR)
- TLSI 0.37
- SDST 0.00
- MACD
- TLSI -0.05
- SDST 0.00
- Stochastic Oscillator
- TLSI 43.44
- SDST 0.00
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).